Home Tags Docetaxel-TH19P01 conjugate

Tag: docetaxel-TH19P01 conjugate

Peptide–drug Conjugate Sudocetaxel Zendusortide Shows Potential as a Single Agent and...

ADC Review | Editorial Team
Sudocetaxel zendusortide, also known as TH1902, is as novel, investigational peptide-drug conjugate (PDC) candidate being developed by Canadian biotech Theratechnologies as single agent and in combination with other anticancer therapies. The drug targets tumors that express the sortilin (SORT1) receptor.
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.

X